

July 7, 2025



Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.

A link to the webcast may be accessed on the Unicycive website under the Investors section: [Events and Presentations](#).

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit [Unicycive.com](https://unicycive.com) and follow us on [LinkedIn](#) and [X](#).

Investor Contact:

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvors.com

Media Contact:

Rachel Visi

Real Chemistry

redery@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.



Source: Unicycive Therapeutics, Inc.